Hepatitis B virus therapy: What’s the future holding for us?

Table 4 Non-nucleoside anti-viral drugs in development for hepatitis B virus

Name	Mechanism	Developed By	Phase
CpAMs	Allosteric Modulation of HBCp	Assembly Biosciences, United States	Pre-clinical
AT61 and AT130	Assembly Activation (Inhibit Capsid Assembly)	Victorian Infectious Diseases Reference Laboratory, Australia	Pre-clinical
BAY41-4109	Assembly Activation (Inhibit Capsid Assembly)	AiCuris, Germany	Phase I
NVR 3-778	HBV Cp Inhibition (cccDNA suppression)	NoviraTheraputics, United States	Phase Ib
NVP018	Cyclophilin inhibition	Tekmira Pharmaceuticals Corporation, Canada	Phase I
TKM-HBV4G and TKM-HBV3G	RNAi	Tekmira Pharmaceuticals Corporation, Canada	Phase I
STING agonists	PRR Activation	Tekmira Pharmaceuticals Corporation, Canada	Pre-clinical
ARC-520	RNAi	Arrowhead Research Corporation, United States	Phase II
ALN-HBV	RNAi	Alnylam Pharmaceuticals, Inc. United States	Pre-clinical
GLS4	Assembly Activation (Inhibit Capsid Assembly)	HEC Pharm Group, China	Phase II (China)
BSBI-25	cccDNA Inhibition	Baruch S. Blumberg Institute, United States	Pre- clinical
Birinapant	SMAC	TetraLogic Pharmaceuticals, United States	Phase I
CPI-431-32	Inhibition of cyclophilin A	Ciclofilin Pharmaceuticals, United States	Pre-clinical
Myrcludex B	HBV entry inhibition	Hepatera Ltd, Russia and MYR GmbH, Germany	Phase II
Simvastatin	HMG CoA reductase inhibitor	University of Oklahoma and United States Veterans Administration	Phase I

RNAi: RNA inhibition; HBV Cp: Hepatitis B virus core protein; PRR: Pattern recognition receptors; SMAC: Synthetic small molecule and peptidomimetic of second mitochondrial-derived activator of caspases.